Organon & Co.
OGNOrganon & Co. (OGN) is a global healthcare company specializing in the development and commercialization of pharmaceutical and biosimilar products. It focuses on women’s health, reproductive rights, and other therapeutic areas, aiming to improve health outcomes through innovative medicines. The company was spun off from Merck & Co. in 2021 to concentrate on its dedicated portfolio of women’s health, biosimilars, and other biopharmaceuticals.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 11, 2026 | $0.02 | 2026-05-11 | 2026-05-11 |
| March 12, 2026 | $0.02 | 2026-02-23 | 2026-02-23 |
| December 11, 2025 | $0.02 | 2025-11-20 | 2025-11-20 |
| September 11, 2025 | $0.02 | 2025-08-15 | 2025-08-15 |
| June 12, 2025 | $0.02 | 2025-05-12 | 2025-05-12 |
Dividends Summary
- Consistent Payer: Organon & Co. has rewarded shareholders with 20 dividend payments over the past 5 years.
- Total Returned Value: Investors who held OGN shares during this period received a total of $4.30 per share in dividend income.
- Latest Payout: The most recent dividend of $0.02/share was paid 37 days ago, on June 11, 2026.
- Yield & Schedule: OGN currently pays dividends quarterly with an annual yield of 0.59%.
- Dividend Growth: Since 2021, the dividend payout has decreased by 92.9%, from $0.28 to $0.02.
- Dividend Reliability: OGN has maintained or increased its dividend for 5 consecutive payments.
Company News
Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether t...
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).
Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share ...
Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines in cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for expansion in the medium to long term.
